X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
USA (Orange Book)
0
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
https://www.reuters.com/business/healthcare-pharmaceuticals/japans-shionogi-says-covid-treatment-did-not-meet-endpoint-late-stage-trial-2024-05-13/
https://www.reuters.com/business/healthcare-pharmaceuticals/ex-pfizer-employee-convicted-insider-trading-covid-drug-trial-2024-01-18/
https://www.fiercepharma.com/pharma/pfizers-covid-revenues-sink-europe-poised-throw-out-22b-expired-paxlovid-courses-report
https://endpts.com/pfizer-sets-paxlovid-price-at-1390-for-5-day-course/
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-lowers-full-year-revenue-forecast-shares-fall-2023-10-13/
https://www.reuters.com/business/healthcare-pharmaceuticals/about-250000-courses-covid-pill-paxlovid-being-administered-per-week-pfizer-ceo-2023-09-26/
https://www.reuters.com/business/healthcare-pharmaceuticals/us-nih-launches-long-covid-trials-pfizers-paxlovid-other-therapies-2023-07-31/
https://www.nationaltribune.com.au/pfizer-s-covid-19-oral-anti-viral-available-to-more-australians-on-the-pharmaceutical-benefits-scheme-from-1-july/
https://www.fiercepharma.com/pharma/former-pfizer-employee-charged-insider-trading-using-advance-information-paxlovid-trial
https://www.cnbc.com/2023/06/29/ex-pfizer-employee-charged-over-trading-on-paxlovid-data.html
https://www.ema.europa.eu/en/documents/overview/paxlovid-epar-medicine-overview_en.pdf
https://www.biospectrumasia.com/news/25/22494/us-fda-approves-first-oral-anti-viral-for-treatment-of-covid-19-in-adults.html
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-pfizers-covid-antiviral-pill-2023-05-25/
https://www.fiercepharma.com/pharma/pfizer-pulls-q1-surprise-sales-covid-products-despite-plummeting-demand
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-merck-trim-prices-china-paxlovid-molnupiravir-reports-2023-04-04/
https://www.prnewswire.com/news-releases/new-yale-study-evaluates-paxlovids-use-in-long-covid-recovery-301777708.html
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-advisers-vote-favor-full-approval-pfizers-covid-pill-paxlovid-2023-03-16/
https://www.reuters.com/business/healthcare-pharmaceuticals/fda-says-pfizer-covid-pill-eua-adolescents-stay-even-after-nod-adults-2023-03-16/
https://www.cnbc.com/2023/03/14/fda-staff-report-says-data-shows-pfizers-covid-treatment-paxlovid-is-effective-in-high-risk-adults.html
https://endpts.com/pfizers-paxlovid-gets-march-fda-advisory-meeting-to-discuss-full-approval/
https://www.pharmatimes.com/news/trio_of_covid-19_treatments_receive_nice_nod_1488312
https://www.fiercepharma.com/marketing/pfizer-launches-new-branded-paxlovid-ad-covid-it-continues-wait-fda-approval
https://endpts.com/fda-axes-requirement-for-positive-covid-test-before-paxlovid-use/
https://www.fiercepharma.com/pharma/abbvies-rinvoq-novartis-kesimpta-and-more-win-china-national-coverage-pfizers-paxlovid-left
https://www.prnewswire.com/news-releases/medscape-survey-finds-reasons-paxlovid-is-underprescribed-for-those-65-and-older-despite-its-effectiveness-against-covid-complications-301720681.html
https://www.globenewswire.com/news-release/2022/12/29/2580481/0/en/Junshi-Biosciences-Announces-NEJM-Publication-of-Results-of-Phase-3-Study-of-VV116-Versus-PAXLOVID-for-Adults-at-High-Risk-for-Progression-to-Severe-COVID-19.html
https://www.reuters.com/business/healthcare-pharmaceuticals/india-based-heteros-paxlovid-generic-gets-who-backing-2022-12-27/
https://www.expresspharma.in/heteros-nirmacom-gets-who-prequalification-for-covid-19-treatment/
https://www.reuters.com/business/healthcare-pharmaceuticals/drug-price-group-slashes-suggested-price-pfizer-covid-treatment-by-80-2022-12-20/
https://endpts.com/us-set-to-pay-nearly-2b-for-pfizers-covid-19-treatment-paxlovid-in-2023/
https://www.fiercepharma.com/pharma/deadly-greed-sen-warren-rep-welch-tear-pfizers-proposed-130-covid-vaccine-price-tag
https://www.reuters.com/world/us/us-pay-pfizer-nearly-2-bln-more-paxlovid-courses-2023-2022-12-13/
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-it-is-working-improve-supply-covid-drug-paxlovid-china-2022-12-13/
https://www.clinicaltrialsarena.com/news/china-nmpa-ascletis-covid-trial/
https://www.fiercebiotech.com/biotech/pfizers-search-paxlovids-covid-busting-sibling-leads-low-profile-antiviral-biotech
https://www.nbcnews.com/health/health-news/paxlovid-treat-long-covid-major-new-study-aims-find-rcna58149
https://www.ema.europa.eu/en/documents/overview/paxlovid-epar-medicine-overview_en.pdf
https://www.fiercepharma.com/pharma/pfizers-paxlovid-access-brought-question-wto-set-discuss-patent-waiver-again
https://www.pharmatimes.com/news/nice_recommends_pfizers_paxlovid_on_nhs_1480943
https://edition.cnn.com/2022/11/16/health/paxlovid-rebound-study/index.html
https://www.reuters.com/world/us/us-cdc-director-tests-positive-covid-19-again-2022-10-31/
https://endpts.com/nih-to-study-pfizers-paxlovid-in-long-covid-as-demand-and-infections-continue-to-fall/
https://www.pharmaceutical-technology.com/news/pfizer-paxlovid-global-fund/
https://www.prnewswire.com/news-releases/paxlovid-significantly-reduces-covid-19-hospitalizations-and-deaths-301630438.html
https://www.outlookindia.com/business/zenara-pharma-launches-generic-of-paxlovid-for-covid-19-in-india-news-222189
https://health.economictimes.indiatimes.com/news/pharma/study-pfizer-covid-pill-showed-no-benefit-in-younger-adults/93766905
https://www.fiercepharma.com/manufacturing/paxlovid-production-pfizer-partners-chinese-company-huahai-which-coming-fda-ban
https://endpts.com/pfizers-paxlovid-only-helped-seniors-avoid-hospitalization-and-death-new-nejm-study-finds/
https://www.fiercepharma.com/pharma/fda-wants-pfizer-study-covid-rebound-effect-longer-course-paxlovid
Market Place
Share 
